written on 06.03.2014

On India trip, U.S. diplomat cites 'concern' about anti-patent actions


One of India&#39;s solutions to get lower-cost meds for its impoverished and uninsured<span style="font-size: 13px;">–compulsory licenses–has ignited drugmakers&#39; ire. And with an Indian committee currently assessing a batch of patented drugs as compulsory licensing candidates, the U.S. is fighting back–politely, at least so far.</span>